ArticleJournal of assisted reproduction and genetics2026
Artificial activation of clinically failed human oocytes enables euploid blastocyst formation.
Article in Journal of assisted reproduction and genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clinically failed human oocytes can be repurposed via in vitro maturation and artificial oocyte activation to generate euploid blastocysts, establishing an ethically unrestricted embryo resource, despite persistent challenges in deriving stem cell lines under feeder-free conditions. PURPOSE: Can clinically failed oocytes, usually discarded during ICSI, be utilized to generate blastocysts suitable for the derivation of human embryonic stem cells (hESCs) and parthenogenetic embryonic stem cells (phESCs) through in vitro maturation (IVM) and artificial oocyte activation (AOA)?
methodsThis prospective study included 716 immature or failed-to-fertilize (FF) oocytes donated by 185 patients undergoing 199 ICSI cycles. A total of 475 oocytes underwent IVM followed by AOA using calcium ionophore and 6-DMAP. Embryonic/parthenogenetic development was monitored through day 7. Blastocysts were graded morphologically, vitrified and assessed for chromosomal content via PGT-A. Inner cell masses (ICMs) were isolated and cultured under feeder-free, GMP-compliant conditions for hESC/phESC derivation.
resultsAOA led to a 65.9% activation rate and 4.8% blastocyst formation rate, with higher efficiency in FF oocytes (activation: 77.9%, blastocyst: 7.2%) compared to IVM oocytes (GV, activation: 63.9%, blastocyst: 1.2%; MI, activation: 58.5%, blastocyst: 4.2%). Nearly half of the 15 blastocysts (47%) formed were euploid (four from FF and three from IVM oocytes), confirming the viability of using clinically discarded oocytes. Despite obtaining euploid blastocysts, no stem cell lines were derived successfully. Nevertheless, the process established a cryopreserved embryo bank using ethically sourced and legally unrestricted biological material.
conclusionsAOA of clinically failed oocytes enables the formation of euploid blastocysts that may be suitable for hESC and phESC derivation. While derivation efficiency under feeder-free conditions remains a challenge, this strategy potentially offers an ethically sound and logistically feasible approach for expanding stem cell resources, particularly valuable in regions with legal constraints on embryo research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.